TP53 and cancer: Accordingly, in almost all cancers, both the RB and p53 pathways are disabled by deletion or mutation of ARF, over-expression of Human double minute 2 (Hdm2), which ubiquitinates p53 and facilitates degradation by proteasome, or mutation and/or deletion of p53, to permit cancer cell survival [13].